The forward progression and regulation in legal cannabis and marijuana stocks is driving the industry to new heights. It’s also allowing current marijuana stocks to battle through resistances levels as things such as expansion, higher quality marijuana goods, innovative product development are increasing in popularity with consumers worldwide. Here are three marijuana stocks that are taking their business to new heights in the industry: PotNetwork Holdings, Inc. (POTN), GT Biopharma, Inc. (OXISD) and 22nd Century Group, Inc. (XXII).
PotNetwork Holding, Inc. (POTN) has been striding in the industry through its subsidiary Diamond CBD. The company recently announced that its Q2 and year to date operating results and the company reported revenues of over $5 million for the first 6 months of fiscal 2017 and a net profit of $369,237. The company closed the first half of 2017 with a positive net cash flow of $395,009. The company also put out a recent press release stating they have engaged with a PCAOB registered CPA firm to audit its financials.
“We believe that the timing for this action is now. In consideration of the amount of momentum built up over the past 6 months, coupled with reported revenues of $5,077,625 for the first 6 months of fiscal 2017, the only logical next step was to initiate the auditing process, whereby the market can recognize the significance and legitimacy of the Company’s recent growth,” stated Gary Blum, Chief Executive Officer, PotNetwork Holding, Inc.
Since the beginning of May, (POTN) has seen a price per share increase of 257.64%. On May 4th the stock saw lows of $0.017, to Thursday’s (9/7) opening price of $0.0608.
GT Biopharma, Inc. (OXISD) announced on Thursday (9/7) that they have appointed a new Chief Medical Officer (CMO) to their executive team. The company appointed former Pfizer CMO/Vice President and Senior Director, Dr. Raymond Urbanksi. Dr. Urbanksi spent eight years with Pfizer and oversaw the company’s breast cancer products and a variety of other products.
“Now we complete our executive management team with another world class executive in Dr. Raymond Urbanski as our new CMO. His expertise in oncology assets and quick-to-market 505(b)2 products is timely for GT Biopharma Inc. Ray’s big pharma and biotech expertise is custom made for the assets of GT Biopharma. He will be instrumental in helping to guide our highly sought after oncology BiKE and TriKE platform technologies to commercial success. We are excited to have our “Dream Team” in place,” Mr. Anthony Cataldo stated.
In the last two weeks of trading, (OXISD) has seen a price per share increase of 77.39%, from lows of $5.75 on Aug. 23rd to Thursday’s daily highs (9/7) of $10.20.
22nd Century Group, Inc. (XXII) is a plant biotechnology company that is focused on genetic engineering and plant breeding which permits the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The company’s main goal in marijuana is to develop a proprietary cannabis strain for new medicines and agriculture crops.
“More than $100 Million of independent research has demonstrated that 22nd Century’s proprietary Very Low Nicotine tobacco could save many millions of lives and will prevent future generations of young people from becoming addicted to cigarettes,” stated Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “22nd Century’s technology is proven. The FDA plan is already feasible. The time to implement a mandate of Very Low Nicotine tobacco in all combustible cigarettes sold in the United States has arrived.”
In the last month of trading, (XXII) has increased 70.80% from lows of $1.37 on July 26th to intra day highs during Thursday’s (9/7) trading session of $2.34.
MarijuanaStocks.com owned by MAPH Enterprises LLC., a Florida Corporation that has been compensated $75,000 (CASH) by Potnetwork Holdings, Inc. via First Capital Ventures, Inc. an affiliate company for or “ZERO” shares of restricted or unrestricted common shares. We have been previously paid $21,000 (CASH) for coverage on Potnetwork Holdings, which has since expired. MAPH Enterprises LLC has been compensated $550,000 by GT Biopharma, Inc. (OXISD) for a period beginning August 1st, 2017 and ending October 1st, 2017 to publicly disseminate information about GT Biopharma, Inc. (OXISD). We own zero shares of (POTN)/(OXISD). We may buy or sell additional shares of (POTN)/(OXISD) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.